Opportunity ID: 322672

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-20-061
Funding Opportunity Title: Co-infection and Cancer (R21 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.393 — Cancer Cause and Prevention Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Nov 22, 2019
Last Updated Date: Nov 22, 2019
Original Closing Date for Applications: Jan 07, 2023
Current Closing Date for Applications: Jan 07, 2023
Archive Date: Feb 12, 2023
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Independent school districts
City or township governments
Public housing authorities/Indian housing authorities
Others (see text field entitled “Additional Information on Eligibility” for clarification)
For profit organizations other than small businesses
Private institutions of higher education
State governments
County governments
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be given to investigations of co-infections with known oncogenic agents (e.g., Helicobacter pylori [H. pylori] and Epstein Barr virus [EBV]; excluding human immunodeficiency virus [HIV]) and of co-infections that engendered novel opportunities for prevention and treatment. Coinfection is defined as the occurrence of infections by two or more infectious (pathogenic or nonpathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-061.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Folder 322672 Full Announcement-PAR-20-061 -> PAR-20-061-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-E Use for due dates on or before May 24, 2020 PKG00256777 Feb 17, 2020 May 24, 2020 View
FORMS-F Use for due dates on or before January 24, 2022 PKG00259762 Feb 17, 2020 Jan 24, 2022 View
FORMS-G Use for due dates on or before January 24, 2023 PKG00270290 Nov 16, 2021 Jan 24, 2023 View
FORMS-H Use for due dates on or after January 25, 2023 PKG00278098 Nov 08, 2022 Jan 07, 2023 View

Package 1

Mandatory forms

322672 RR_SF424_2_0-2.0.pdf

322672 PHS398_CoverPageSupplement_4_0-4.0.pdf

322672 RR_OtherProjectInfo_1_4-1.4.pdf

322672 PerformanceSite_2_0-2.0.pdf

322672 RR_KeyPersonExpanded_2_0-2.0.pdf

322672 PHS398_ResearchPlan_4_0-4.0.pdf

Optional forms

322672 RR_Budget_1_4-1.4.pdf

322672 RR_SubawardBudget30_1_4-1.4.pdf

322672 PHS398_ModularBudget_1_2-1.2.pdf

322672 PHS_AssignmentRequestForm_2_0-2.0.pdf

Package 2

Mandatory forms

322672 RR_SF424_2_0-2.0.pdf

322672 PHS398_CoverPageSupplement_5_0-5.0.pdf

322672 RR_OtherProjectInfo_1_4-1.4.pdf

322672 PerformanceSite_2_0-2.0.pdf

322672 RR_KeyPersonExpanded_2_0-2.0.pdf

322672 PHS398_ResearchPlan_4_0-4.0.pdf

322672 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

322672 RR_Budget_1_4-1.4.pdf

322672 RR_SubawardBudget30_1_4-1.4.pdf

322672 PHS398_ModularBudget_1_2-1.2.pdf

322672 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 3

Mandatory forms

322672 RR_SF424_5_0-5.0.pdf

322672 PHS398_CoverPageSupplement_5_0-5.0.pdf

322672 RR_OtherProjectInfo_1_4-1.4.pdf

322672 PerformanceSite_4_0-4.0.pdf

322672 RR_KeyPersonExpanded_4_0-4.0.pdf

322672 PHS398_ResearchPlan_4_0-4.0.pdf

322672 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

322672 RR_Budget_3_0-3.0.pdf

322672 RR_SubawardBudget30_3_0-3.0.pdf

322672 PHS398_ModularBudget_1_2-1.2.pdf

322672 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 4

Mandatory forms

322672 RR_SF424_5_0-5.0.pdf

322672 PHS398_CoverPageSupplement_5_0-5.0.pdf

322672 RR_OtherProjectInfo_1_4-1.4.pdf

322672 PerformanceSite_4_0-4.0.pdf

322672 RR_KeyPersonExpanded_4_0-4.0.pdf

322672 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

322672 RR_Budget_3_0-3.0.pdf

322672 RR_SubawardBudget30_3_0-3.0.pdf

322672 PHS398_ModularBudget_1_2-1.2.pdf

322672 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-09T10:57:42-05:00

Share This Post, Choose Your Platform!

About the Author: